Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

14.84 -0.29 (-1.92%)
Official Closing Price Updated: 7:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
One Ultra-Cheap High-Yield Dividend Stock to Buy
Now may be a good time for dividend investors to consider loading up on this stock. 
Via The Motley Fool
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach
Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,... 
Via Benzinga
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
Via Benzinga
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
From Takeda Pharmaceutical Company Limited
Via Business Wire
Why Is Neurocrine Biosciences Stock Trading Lower Today?
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)  
Via Benzinga
Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy
The FDA approved Takeda Pharmaceutical Co Ltd's (NYSE: 
Via Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
Via Benzinga
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
Via Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
Via Benzinga
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
3 Promising Biotech Stocks Flying Under the Radar
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
Via Benzinga
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.
Analysts say Alkermes' drug is clearly active. But investors have concerns. 
Via Investor's Business Daily
Earnings Scheduled For October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion. 
Via Benzinga
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin... 
Via Talk Markets
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners
Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF). 
Via Benzinga
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga
Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial
Following discussions with the FDA, Takeda Pharmaceutical Co Ltd (NYSE: TAK) will voluntarily withdraw Exkivity (mobocertinib)  
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.